Entera Bio Ltd (ENTX) is not a good buy for a beginner, long-term investor at this time. The stock shows weak technical indicators, poor financial performance, and lacks positive catalysts or strong trading signals. Additionally, the company's fundamentals and lack of growth trends make it unsuitable for long-term investment.
The technical indicators for ENTX are bearish. The MACD is negative and expanding, RSI is neutral at 33.363, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.028), with resistance levels at R1: 1.41 and R2: 1.528. Overall, the technical setup does not suggest a strong buying opportunity.

NULL identified. There are no recent news updates, no significant insider or hedge fund activity, and no recent congress trading data.
The company's financials are weak, with revenue dropping to 0 (-100% YoY), EPS declining by -12.50% YoY, and net income remaining negative. Technical indicators are bearish, and the stock's historical and implied volatility are extremely high, indicating significant risk.
In Q3 2025, the company's revenue dropped to 0 (-100% YoY), net income improved slightly to -$3.2M (+5.93% YoY), and EPS declined to -0.07 (-12.50% YoY). Gross margin remains at 0%. These metrics indicate poor financial health and no growth trends.
No recent analyst ratings or price target changes are available for ENTX.
